Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- A Practical Approach to Veterinary Vaccine Development and Registration in the EU Sets March 2027 Online Training DateRising demand for veterinary biologics creates opportunities for vaccine development expertise and practical EU market authorization training.
- Patient-Derived Xenograft/PDX Model Market - Global Forecast 2026-2032Opportunities include integrated PDX platforms, humanized models, organoid pairing, AI analytics, annotated biobanks, precision oncology, and expansion across emerging research hubs.
- The U.S. FDA grants orphan drug designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for treatment of endogenous Cushing's syndromeThe U.S. FDA has granted Orphan Drug Designation for asedebart (Lu AG13909), Lundbeck's novel investigational anti-ACTH monoclonal antibody, for the treatment of endogenous Cushing's syndrome Endogenous Cushing's Syndrome is a rare endocrine disorder driven in most cases by excess...
- DJS Law Group LLPCapricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPRThe DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated...
- Persica Pharmaceuticals publishes new analysis of assay sensitivity in disc microbiology studies, reinforcing the potential for PP353 in vertebrogenic Lumbar Back PainLondon, UK, 11 September 2026 - Persica Pharmaceuticals Limited (“Persica”), a clinical-stage biotechnology company developing PP353, a targeted, non-opioid treatment for vertebrogenic Lumbar Back Pain (vLBP), today announced publication of a new analysis examining why previous disc microbiology studies have reported divergent findings on bacterial presence in spinal discs.
- Nicox annonce l’acceptation pour examen en Chine de la NDA de NCX 4701 La date PDUFA correspond à la date cible à laquelle la Food and Drug Administration (FDA) américaine prévoit d’achever la revue d’une demande d’autorisation de mise sur le marché (NDA) et de rendre sa décision, conformément au Prescription Durg User Fee Act (PDUFA).
- Nicox Announces NCX 470 NDA in China Accepted for Review1 A PDUFA date is the target date by which the U.S. Food and Drug Administration (FDA) aims to complete its review and issue a decision on a New Drug Application (NDA) under the Prescription Drug User Fee Act (PDUFA).
- MegazoneCloudMegazoneCloud Begins Building Hanmi Pharmaceutical's Quality Assurance AI Agent with 'AIR Studio'Fine-tunes the Korean model Solar and deploys it on its own AI platform, AIR Studio, to automate quality-document operations Part of the MSIT•NIPA 'AX One-Stop Voucher Program'; consortium formed with Hanmi Pharmaceutical, Samsung SDS, and Selectstar SEOUL, South Korea, Sept. 9, 2026...
- Kaplan Fox & Kilsheimer LLPKaplan Fox Urges Investors of Fulcrum Therapeutics, Inc. (FULC) with Losses to Contact the FirmKaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC).CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATIONIf you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us. You may also...
- UNCY Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Unicycive Therapeutics, Inc. Class Action LawsuitRobbins LLP is Investigating Allegations that Unicycive Therapeutics, Inc. Failed to Properly Inspect its Third-Party Vendor's Manufacturing Facility
- Cardiol Therapeutics Inc.Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities CommissionCardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has filed a preliminary short...
- Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment ConferenceAssembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will present during the H.C. Wainwright & Co. 28th Annual Global Investment Conference at 8:30 a.m. Eastern Time on September 16, 2026.